Financial Performance - The company's revenue for Q1 2023 was ¥412,587,989.38, a decrease of 50.15% compared to ¥827,689,742.45 in the same period last year[5] - Net profit attributable to shareholders was ¥21,413,081.32, down 87.92% from ¥177,239,159.96 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥10,970,668.67, a decline of 93.69% compared to ¥173,781,718.39 in the previous year[5] - Basic and diluted earnings per share were both ¥0.0535, down 87.91% from ¥0.4425 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 412,587,989.38, a decrease of 50.16% compared to CNY 827,689,742.45 in the same period last year[18] - Net profit for Q1 2023 was CNY 15,591,014.71, a decline of 93.25% compared to CNY 231,157,344.48 in Q1 2022[20] Cash Flow - The net cash flow from operating activities was ¥61,732,450.68, a significant improvement from a negative cash flow of ¥152,146,040.01 in the same period last year, representing a 140.57% increase[5] - Cash inflow from operating activities totaled ¥672,021,146.28, compared to ¥400,535,151.96 in the prior period, indicating a 67.6% increase[24] - Cash outflow from operating activities was ¥610,288,695.60, up from ¥552,681,191.97, reflecting a 10.4% increase[24] - The net cash flow from investing activities was -¥16,733,022.17, a decline from the previous period's net cash flow of ¥48,001,363.82[24] - Cash inflow from financing activities amounted to ¥20,900,000.00, a substantial increase from ¥2,785,000.00 in the prior period[25] - The net cash flow from financing activities was ¥11,309,552.97, compared to -¥3,316,867.59 previously, marking a turnaround[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,462,543,924.22, a decrease of 7.59% from ¥3,746,874,320.81 at the end of the previous year[5] - The total current assets decreased from ¥3,388,588,398.52 to ¥3,096,765,090.08, a decline of approximately 8.59%[15] - The company's fixed assets decreased from ¥160,948,219.68 to ¥158,360,097.08, a reduction of about 1.97%[15] - Total liabilities decreased to CNY 1,172,440,259.27 from CNY 1,474,119,803.00, a decline of 20.49%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,725[9] - The largest shareholder, Shanghai Lanwei Investment Co., Ltd., holds 37.34% of the shares, totaling 149,554,017 shares[9] Other Income and Expenses - The company reported a significant increase in other income, which rose by 374.26% to ¥16,326,865.98, primarily due to government subsidies and tax refunds received during the period[7] - The company experienced a 741.55% increase in credit impairment losses, amounting to ¥35,517,924.09, attributed to slower receivables collection[7] - The company's R&D expenses for Q1 2023 were CNY 10,753,900.80, a decrease of 13.96% from CNY 12,493,191.61 in the previous year[18] Goodwill and Investments - The goodwill increased by 42.96% to ¥25,214,760.47, mainly due to the acquisition of Beijing Mingdi Biomedical Technology Co., Ltd.[7] - Cash paid for the purchase of fixed assets, intangible assets, and other long-term assets decreased by 62.13% to ¥13,638,166.75 compared to the previous period[8] - Cash paid for investments dropped by 96.14% to ¥11,102,112.89, primarily due to a decrease in the amount spent on financial products[8]
兰卫医学(301060) - 2023 Q1 - 季度财报